Oracle Health Sciences

Oracle unveils new version of ClearTrial Plan and Source Enterprise

Wednesday, February 6, 2013 01:21 PM

Oracle Health Sciences has released Oracle Health Sciences ClearTrial Plan and Source Enterprise Edition Cloud Service 5.0, the latest version of the cloud-based clinical trial operations solution that enables life sciences organizations to plan, source and track clinical projects and financial performance via a single, integrated platform.

More... »

MD Anderson selects Oracle applications and tech to help transform cancer care

Friday, February 1, 2013 11:26 AM

The University of Texas MD Anderson Cancer Center, a center devoted exclusively to cancer patient care, research, education and prevention, has selected Oracle Health Sciences applications and Oracle technology as the foundation for an organization-wide analytics initiative designed to enable a new generation of personalized cancer treatment that improves outcomes. 

More... »

UPMC selects Oracle to power enterprise healthcare analytics initiative

Monday, October 1, 2012 02:49 PM

UPMC, a $10 billion integrated global health enterprise based in Pittsburgh, Penn., has selected Oracle Health Sciences applications and Oracle technology and hardware as a key part of the foundation for its new five-year, $100 million enterprise healthcare analytics initiative.

More... »

Techsol’s ‘QuickLaunch’ aims to achieve faster early-phase clinic automation

Monday, July 23, 2012 02:25 PM

Techsol, a technology service provider for the pharmaceutical and life sciences industry, has released “QuickLaunch,” an accelerated Oracle Health Sciences' LabPas deployment package that enables pharmaceutical companies, CROs and academic medical research institutions to swiftly automate their current early phase clinical units in compliance with the FDA.

More... »

Oracle launches new version of clinical development analytics

Wednesday, March 28, 2012 11:42 AM

Oracle Health Sciences has introduced the newest version of Oracle Health Sciences Clinical Development Analytics in an effort to help health sciences organizations increase the productivity and effectiveness of their product development programs.

More... »

Oracle Institute and Oracle Labs announce research projects

Friday, February 3, 2012 01:27 PM

Oracle Health Sciences Institute, in partnership with Oracle Labs, has announced its first group of research projects, which includes initiatives with Brigham and Women’s Hospital and Harvard Medical School, the Coalition Against Major Diseases (CAMD) at the Critical Path Institute and the Human-Computer Interaction Lab (HCIL) at the University of Maryland.

More... »

Oracle Health Sciences releases Omics Data Bank

Tuesday, January 24, 2012 02:55 PM

Oracle Health Sciences has released the Oracle Health Sciences Omics Data Bank, a molecular data model, part of Oracle Health Sciences’ Translational Research Center.  The new data model provides integration and analysis of cross-platform omics data to support translational research.

More... »

Oracle launches OutcomeLogix On Demand 3.0

Tuesday, October 18, 2011 02:10 PM

Oracle Health Sciences has launched Oracle Health Sciences OutcomeLogix On Demand 3.0, a web-based, scalable data collection system that enables life science companies and contract research organizations to efficiently capture accurate therapy outcome information from health care providers, as well as patients in late-stage studies.

More... »

Oracle Health Sciences launches spend monitor solution

Tuesday, September 6, 2011 12:08 PM

Oracle Health Sciences has launched Oracle’s spend monitor solution, which helps life sciences organizations increase transparency and comply with disparate state and federal regulations and industry guidelines governing sales and marketing spend, as well as financial arrangements with healthcare providers.

More... »

Oracle to Acquire Phase Forward for $685M

Friday, April 16, 2010 02:37 PM

Business software giant Oracle, already a player in the eClinical space, plans to acquire market leader Phase Forward in a deal valued at approximately $685 million—or $17 per share in cash.

More... »